European Regulatory Committee Recommends Orphan Drug Status for GPC Biotech's Anticancer Monoclonal Antibody
GPC Biotech AG announced that the Committee for Orphan Medicinal Products (COMP) of the European Medicines Agency (EMEA) has recommended the granting of orphan medicinal product designation for the anticancer monoclonal antibody 1D09C3 for the treatment of multiple myeloma. The orphan drug status becomes effective when the European Commission has approved this recommendation. 1D09C3 is currently in a Phase 1 clinical program that is evaluating the antibody in patients with relapsed or refractory B-cell lymphomas, including Hodgkin's and non-Hodgkin's lymphomas, who have failed prior standard therapy.
1D09C3 is an anti-MHC (major histocompatibility complex) class II monoclonal antibody. 1D09C3 binds to MHC class II molecules on the cell surface and in preclinical studies appears to selectively kill activated, proliferating tumor cells, which include B-cell and T-cell lymphomas. In preclinical studies, 1D09C3 has been shown to induce programmed cell death and does not require a functioning immune system for its cell-killing effect. A Phase 1 clinical program evaluating 1D09C3 in patients with relapsed or refractory B-cell lymphomas who have failed prior standard therapy, is currently underway at several major cancer centers in Europe. 1D09C3 has been granted orphan medicinal product designation for the treatment of Hodgkin's lymphoma and chronic lymphocytic leukemia.
Topics
Organizations
Other news from the department research and development

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
More news from our other portals
Last viewed contents
Speedel Receives Major Development Milestones From Novartis - Equity participation and cash payment for Aliskiren SPP100

New class of drugs holds promise for combating antibiotic resistance
Swedish Orphan Biovitrum and Biomodels to develop assay for mucositis risk in cancer treatment
Bridging that Gap Between Research and Market - Europe is well positioned to spearhead the development of a bio-based economy but must invest in demonstration activities to gain a competitive edge, says new study
Bonn scientists discover new hemoglobin type - Instruments falsely report anoxia in affected people
ADC Therapeutics to Move Antibody Drug Conjugate ADCT-401 for Prostate Cancer into Human Clinical Trials
RVX-208 Exploratory Study Illustrates Early Potential for Alzheimer's Disease
Addex Parkinson's Product Progressing in Early Clinical Trials
Rhenovia files patents for new treatment of Huntington’s disease based on its biosimulation platform
